CA2298811A1 - Procede de traitement des greffons - Google Patents

Procede de traitement des greffons Download PDF

Info

Publication number
CA2298811A1
CA2298811A1 CA002298811A CA2298811A CA2298811A1 CA 2298811 A1 CA2298811 A1 CA 2298811A1 CA 002298811 A CA002298811 A CA 002298811A CA 2298811 A CA2298811 A CA 2298811A CA 2298811 A1 CA2298811 A1 CA 2298811A1
Authority
CA
Canada
Prior art keywords
graft
nucleic acid
cells
vectors
grafts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002298811A
Other languages
English (en)
Inventor
Jeffrey M. Isner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Elizabeths Medical Center of Boston Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2298811A1 publication Critical patent/CA2298811A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

La présente invention concerne un procédé de traitement des greffons consistant à introduire un acide nucléique codant un agent angiogénique dans les cellules du greffon. Le greffon peut être traité ex vivo, puis transplanté dans le donneur ou il peut être traité après la transplantation. Le greffon peut être autologue, allogénique, xénogénique ou il peut s'agir d'un greffon obtenue par synthèse de tissus (organe "bio-artificiel"). L'acide nucléique peut être introduit dans les cellules cultivées utilisées pour former le greffon obtenu par synthèse de tissus. L'expression de l'agent angiogénique par les cellules du greffon facilite la croissance de nouveaux vaisseaux sanguins (angiogenèse), ce qui permet d'irriguer le greffon et donc d'augmenter les chances de survie de ce dernier.
CA002298811A 1997-07-31 1998-07-31 Procede de traitement des greffons Abandoned CA2298811A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5438697P 1997-07-31 1997-07-31
US60/054,386 1997-07-31
PCT/US1998/015971 WO1999006073A1 (fr) 1997-07-31 1998-07-31 Procede de traitement des greffons

Publications (1)

Publication Number Publication Date
CA2298811A1 true CA2298811A1 (fr) 1999-02-11

Family

ID=21990704

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002298811A Abandoned CA2298811A1 (fr) 1997-07-31 1998-07-31 Procede de traitement des greffons

Country Status (5)

Country Link
EP (1) EP1009441A1 (fr)
JP (1) JP2001511462A (fr)
AU (1) AU8763898A (fr)
CA (1) CA2298811A1 (fr)
WO (1) WO1999006073A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024415A2 (fr) 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methodes de regulation de l'angiogenese et de l'integrite vasculaire a l'aide de ligands des recepteurs trk
CA2377541A1 (fr) * 1999-06-25 2001-01-04 Eduardo N. Mitrani Procede permettant d'induire une angiogenese au moyen de micro-organes
US7468242B2 (en) 2001-11-05 2008-12-23 Medgenics, Inc. Dermal micro organs, methods and apparatuses for producing and using the same
US8088568B2 (en) 2001-11-05 2012-01-03 Medgentics, Inc. Dermal micro-organs, methods and apparatuses for producing and using the same
US8501396B2 (en) 2001-11-05 2013-08-06 Medgenics Medical Israel Ltd. Dermal micro-organs, methods and apparatuses for producing and using the same
JP5226923B2 (ja) * 2002-04-15 2013-07-03 株式会社セルシード 心筋細胞シートによる心筋症治療薬
EP2377403A1 (fr) 2003-05-01 2011-10-19 Medgenics, Inc. Micro-organe dermique génétiquement modifié exprimant le facteur VIII
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
JP2010504909A (ja) 2006-09-14 2010-02-18 メドジェニクス・メディカル・イスラエル・リミテッド 長期持続性の医薬製剤
CN103260649A (zh) 2010-06-15 2013-08-21 迈德詹尼克斯医疗以色列有限公司 长效药物制剂
EP2600901B1 (fr) 2010-08-06 2019-03-27 ModernaTX, Inc. Compositions pharmaceutiques a base d'acides nucléiques modifiés et leur utilisation medicale
ES2737960T3 (es) 2010-10-01 2020-01-17 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados y sus usos
WO2012052953A1 (fr) 2010-10-20 2012-04-26 Fondazione Centro San Raffaele Del Monte Tabor Miarn
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3682905B1 (fr) 2011-10-03 2021-12-01 ModernaTX, Inc. Nucléosides, nucléotides et acides nucléiques modifiés et leurs utilisations
EP2791160B1 (fr) 2011-12-16 2022-03-02 ModernaTX, Inc. Compositions de mrna modifiés
RU2014129863A (ru) * 2011-12-21 2016-02-10 Модерна Терапьютикс, Инк. Способы повышения жизнеспособности или увеличения продолжительности жизни органа или экспланта органа
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP4074834A1 (fr) 2012-11-26 2022-10-19 ModernaTX, Inc. Arn à terminaison modifiée
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2926218A1 (fr) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides codant pour un recepteur de lipoproteines de faible densite

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein

Also Published As

Publication number Publication date
WO1999006073A1 (fr) 1999-02-11
AU8763898A (en) 1999-02-22
EP1009441A1 (fr) 2000-06-21
JP2001511462A (ja) 2001-08-14

Similar Documents

Publication Publication Date Title
CA2298811A1 (fr) Procede de traitement des greffons
EP0941125B1 (fr) Procede de regulation de l'angiogenese
US5423778A (en) System and method for transplantation of cells
KR101198189B1 (ko) 진피 미세 기관, 그를 생산 및 이용하기 위한 방법 및 장치
US9095580B2 (en) Compositions and methods for regulating angiogenesis
Andree et al. Plasmid gene delivery to human keratinocytes through a fibrin-mediated transfection system
US20090155229A1 (en) Chondrocyte-based implant for the delivery of therapeutic agents
Jun et al. Prospects for gene therapy in corneal disease
Lau et al. Overexpression of lysyl oxidase to increase matrix crosslinking and improve tissue strength in dermal wound healing
Suda et al. Recipient intramuscular gene transfer of active transforming growth factor-β1 attenuates acute lung rejection
CA2330172A1 (fr) Implant prothetique et techniques d'utilisation aux fins de l'expression de genes therapeutiques
He et al. 199. Circulating Endothelial Progenitor Cells Restore Endothelial Function of Balloon Injured Rabbit Carotid Artery
Malecki et al. 201. Angiogenic Gene Therapy of Coronary Artery Disease-from Bench to the Clinic

Legal Events

Date Code Title Description
FZDE Dead